2025 Q4 -tulosraportti
55 päivää sitten
‧1 t 0 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 302 | - | - | ||
| 141 | - | - | ||
| 598 | - | - | ||
| 100 | - | - | ||
| 865 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 8.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenYet another mountain stage that ends at the top.
·6 t sittenNot much mountain stage today 😀😀- ·2 päivää sittenThe finest mountain stages end there, where the sky begins.
·2 päivää sitten · MuokattuYes, it's going very well in here. There isn't as much idle chatter just like in the Novo chat. I think we are more busy making money? 
·2 päivää sittenNews Today at 9.21 Can rise 77 pct. next year: Analysts see the greatest potential in this Danish stock. Especially one Danish stock is currently being watched closely by many analysts. In fact, analysts at the major financial institutions collectively believe that the stock could become a full 77 pct. more valuable over the coming year. This makes the stock the one among the major Danish stocks in the leading C25 index with the greatest price potential right now. The stock in question is the biotech company Zealand Pharma, which has been challenged over the past year and has fallen by 38 pct. However, analysts have high expectations that the Zealand stock can make a comeback. According to data from the financial service Bloomberg, there are 20 analysts covering the stock. Of these, 12 have a buy recommendation, while seven analysts recommend holding back - neither buying nor selling the stock. Finally, there is one analyst who recommends selling the stock. Together, analysts have an average price target for the Zealand stock of 510.35 kr. Thus, analysts expect the Zealand stock to rise by a good 77 pct. from Friday's closing price of 287.8 kr. A price target is an analyst's expectation of where the stock's price may move in the future. This is typically within the next 12 months. The Danish biotech company Zealand Pharma is developing a range of obesity drugs, where the company has, among other things, entered into a billion-dollar collaboration with the Swiss pharmaceutical giant Roche on the obesity drug Petrelintid. Share:
·2 päivää sittenIf you have followed the analysts' assessments throughout the stock's downturn, there has constantly been a positive sentiment around the stock. Even though it has stalled
·9.4.Great comeback it's having. I'm calling 250 soon though.
·1 päivä sitten2.78% increase today in 🐕 heads. For hell's sake, read their financial report if you're capable of it. ZP is cushioned for fluctuations regarding their cash reserves. Can it shake ZP? The weaklings empty the bag at the same time, nope, but they are financially in a completely different place and will recover. There was a user on mushrooms who saw 250 ahead of them - I think it's those naked cap mushrooms that do it. When you have ZP shares, it's damn not to earn a profit 48!hours after purchase, but suddenly the golden egg is laid that we all partake in via share purchases etc. So users today and unfortunately all other days of the week: Should we buy….. Use your time more rationally and stop asking - ask your mother as sometimes it shines through that they haven't grown hair on …. the chin. It's enough to get long onions from all the hopeless posts, especially Novo and Zealand Pharma So for hell's sake, drop out of stocks if you constantly panic and trade with borrowed money
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
55 päivää sitten
‧1 t 0 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenYet another mountain stage that ends at the top.·6 t sittenNot much mountain stage today 😀😀
- ·2 päivää sittenThe finest mountain stages end there, where the sky begins.·2 päivää sitten · MuokattuYes, it's going very well in here. There isn't as much idle chatter just like in the Novo chat. I think we are more busy making money?
- ·2 päivää sittenNews Today at 9.21 Can rise 77 pct. next year: Analysts see the greatest potential in this Danish stock. Especially one Danish stock is currently being watched closely by many analysts. In fact, analysts at the major financial institutions collectively believe that the stock could become a full 77 pct. more valuable over the coming year. This makes the stock the one among the major Danish stocks in the leading C25 index with the greatest price potential right now. The stock in question is the biotech company Zealand Pharma, which has been challenged over the past year and has fallen by 38 pct. However, analysts have high expectations that the Zealand stock can make a comeback. According to data from the financial service Bloomberg, there are 20 analysts covering the stock. Of these, 12 have a buy recommendation, while seven analysts recommend holding back - neither buying nor selling the stock. Finally, there is one analyst who recommends selling the stock. Together, analysts have an average price target for the Zealand stock of 510.35 kr. Thus, analysts expect the Zealand stock to rise by a good 77 pct. from Friday's closing price of 287.8 kr. A price target is an analyst's expectation of where the stock's price may move in the future. This is typically within the next 12 months. The Danish biotech company Zealand Pharma is developing a range of obesity drugs, where the company has, among other things, entered into a billion-dollar collaboration with the Swiss pharmaceutical giant Roche on the obesity drug Petrelintid. Share:·2 päivää sittenIf you have followed the analysts' assessments throughout the stock's downturn, there has constantly been a positive sentiment around the stock. Even though it has stalled
- ·9.4.Great comeback it's having. I'm calling 250 soon though.·1 päivä sitten2.78% increase today in 🐕 heads. For hell's sake, read their financial report if you're capable of it. ZP is cushioned for fluctuations regarding their cash reserves. Can it shake ZP? The weaklings empty the bag at the same time, nope, but they are financially in a completely different place and will recover. There was a user on mushrooms who saw 250 ahead of them - I think it's those naked cap mushrooms that do it. When you have ZP shares, it's damn not to earn a profit 48!hours after purchase, but suddenly the golden egg is laid that we all partake in via share purchases etc. So users today and unfortunately all other days of the week: Should we buy….. Use your time more rationally and stop asking - ask your mother as sometimes it shines through that they haven't grown hair on …. the chin. It's enough to get long onions from all the hopeless posts, especially Novo and Zealand Pharma So for hell's sake, drop out of stocks if you constantly panic and trade with borrowed money
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 302 | - | - | ||
| 141 | - | - | ||
| 598 | - | - | ||
| 100 | - | - | ||
| 865 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 8.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.2.2025 |
2025 Q4 -tulosraportti
55 päivää sitten
‧1 t 0 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 8.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenYet another mountain stage that ends at the top.·6 t sittenNot much mountain stage today 😀😀
- ·2 päivää sittenThe finest mountain stages end there, where the sky begins.·2 päivää sitten · MuokattuYes, it's going very well in here. There isn't as much idle chatter just like in the Novo chat. I think we are more busy making money?
- ·2 päivää sittenNews Today at 9.21 Can rise 77 pct. next year: Analysts see the greatest potential in this Danish stock. Especially one Danish stock is currently being watched closely by many analysts. In fact, analysts at the major financial institutions collectively believe that the stock could become a full 77 pct. more valuable over the coming year. This makes the stock the one among the major Danish stocks in the leading C25 index with the greatest price potential right now. The stock in question is the biotech company Zealand Pharma, which has been challenged over the past year and has fallen by 38 pct. However, analysts have high expectations that the Zealand stock can make a comeback. According to data from the financial service Bloomberg, there are 20 analysts covering the stock. Of these, 12 have a buy recommendation, while seven analysts recommend holding back - neither buying nor selling the stock. Finally, there is one analyst who recommends selling the stock. Together, analysts have an average price target for the Zealand stock of 510.35 kr. Thus, analysts expect the Zealand stock to rise by a good 77 pct. from Friday's closing price of 287.8 kr. A price target is an analyst's expectation of where the stock's price may move in the future. This is typically within the next 12 months. The Danish biotech company Zealand Pharma is developing a range of obesity drugs, where the company has, among other things, entered into a billion-dollar collaboration with the Swiss pharmaceutical giant Roche on the obesity drug Petrelintid. Share:·2 päivää sittenIf you have followed the analysts' assessments throughout the stock's downturn, there has constantly been a positive sentiment around the stock. Even though it has stalled
- ·9.4.Great comeback it's having. I'm calling 250 soon though.·1 päivä sitten2.78% increase today in 🐕 heads. For hell's sake, read their financial report if you're capable of it. ZP is cushioned for fluctuations regarding their cash reserves. Can it shake ZP? The weaklings empty the bag at the same time, nope, but they are financially in a completely different place and will recover. There was a user on mushrooms who saw 250 ahead of them - I think it's those naked cap mushrooms that do it. When you have ZP shares, it's damn not to earn a profit 48!hours after purchase, but suddenly the golden egg is laid that we all partake in via share purchases etc. So users today and unfortunately all other days of the week: Should we buy….. Use your time more rationally and stop asking - ask your mother as sometimes it shines through that they haven't grown hair on …. the chin. It's enough to get long onions from all the hopeless posts, especially Novo and Zealand Pharma So for hell's sake, drop out of stocks if you constantly panic and trade with borrowed money
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 302 | - | - | ||
| 141 | - | - | ||
| 598 | - | - | ||
| 100 | - | - | ||
| 865 | - | - |
Välittäjätilasto
Dataa ei löytynyt